Cytology versus high-risk HPV testing for follow-up of HPV-positive women without CIN

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 1, 2008, Pages 96-100

  Kimball, Kristopher J ^a   Huh, Warner K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cervix; CIN; Clinical management; Cytology; High risk hpv testing

Indexed keywords

ARTICLE; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MICROBIOLOGICAL EXAMINATION; PAPANICOLAOU TEST; PRACTICE GUIDELINE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; WOMEN'S HEALTH;

EID: 38949186727     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0009     Document Type: Article

References (23)

1. Cervical Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2005:1-61.
2. Fleurence RL, Dixon JM, Milanova TF, et al. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol 2007;196:206-212.
3. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-1392.
4. Guido R, Schiffman M, Solomon D, et al. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003;188:1401-1405.
5. Partridge EE, Abu-Rustum N, Campos S, et al. The NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer Screening, version 1, 2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/cervical_screening.pdf. Accessed October 8, 2007.
6. Wright TC Jr, Cox JT, Massad LS, et al. 2001 consensus guidelines for the management of women with cetvical cytological abnormalities. J Low Genit Tract Dis 2002;6:127-143.
7. Cuzick J, Clavel C, Petty KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101.
8. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-819.
9. Wright TC Jr. Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obstet Gynecol 2007;50:313-323.
10. Davey E, Barratt A, Irwig I, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006;367:122-132.
11. Taylor S, Kuhn L, Dupree W, et al. Direct comparison of liquid-based and conventional cytology in a South African screening trial. Int J Cancer 2006;118:957-962.
12. Nobbenhuis MA, Walboomers JM, Heimerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-25.
13. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
14. Pretorius RG, Peterson P, Azizi F, et al. Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less. Am J Obstet Gynecol 2006;195:1260-1265.
15. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-309.
16. Ho GY, Bierman R, Beardsley L, et al. Natural history of cetvicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
17. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;191:182-192.
18. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-1757.
19. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology intetpretations. Am J Obstet Gynecol 2003;188:1393-1400.
20. Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003;188:1406-1412.
21. Ismail SM, Colclough AB, Dinnen JS, et al. Reporting cervical intra-epithelial neoplasia (CIN): intra- and interpathologist variation and factors associated with disagreement. Histopathology 1990;16:371-376.
22. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-1079.
23. Saraiya M, Irwin KL, Carlin L, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer 2007;110:1024-1032.